These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25989677)

  • 1. [Research progress of squamous cell carcinoma of head and neck EGFR targeted therapy resistance mechanisms].
    Song Q; Li X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(2):184-90. PubMed ID: 25989677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance.
    Boeckx C; Baay M; Wouters A; Specenier P; Vermorken JB; Peeters M; Lardon F
    Oncologist; 2013; 18(7):850-64. PubMed ID: 23821327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapy of Head and Neck Cancer.
    Rieke DT; Klinghammer K; Keilholz U
    Oncol Res Treat; 2016; 39(12):780-786. PubMed ID: 27889751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN).
    Price KA; Cohen EE
    Oral Oncol; 2015 May; 51(5):399-408. PubMed ID: 25725588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging.
    van Dijk LK; Boerman OC; Kaanders JH; Bussink J
    Clin Cancer Res; 2015 Aug; 21(16):3602-9. PubMed ID: 25931452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor biology in head and neck cancer.
    Kalyankrishna S; Grandis JR
    J Clin Oncol; 2006 Jun; 24(17):2666-72. PubMed ID: 16763281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
    Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
    Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
    Machiels JP; Schmitz S
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas.
    Tepper SR; Zuo Z; Khattri A; Heß J; Seiwert TY
    Oral Oncol; 2016 May; 56():62-70. PubMed ID: 27086488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma.
    Kao J; Sikora AT; Fu S
    Curr Cancer Drug Targets; 2009 Dec; 9(8):931-7. PubMed ID: 20025602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
    Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
    Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas.
    Martinez-Useros J; Garcia-Foncillas J
    Oral Oncol; 2015 May; 51(5):423-30. PubMed ID: 25753560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.
    Niehr F; Weichert W; Stenzinger A; Budach V; Tinhofer I
    J Transl Med; 2015 Apr; 13():106. PubMed ID: 25890004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.